Ankita Jain

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Metastatic Renal Cell Carcinoma

Chronic Kidney Disease

Ejection Fraction

Top Venues

Indian journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Jiten Jaipuria, Ankita Jain, Shashikant Gupta, Nripesh Sadasukhi, Priyatham Kasaraneni, Amitabh Singh, Kush Gupta, Girish Sharma, Vineet Talwar, Sudhir Kumar Rawal
jomfp2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience. Indian journal of cancer (2024)
Jiten Jaipuria, Ankita Jain, Shashikant Gupta, Nripesh Sadasukhi, Priyatham Kasaraneni, Amitabh Singh, Kush Gupta, Girish Sharma, Vineet Talwar, Sudhir Kumar Rawal
2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience. Indian journal of cancer 60 (4) (2024)
Jiten Jaipuria, Ankita Jain, Shashikant Gupta, Nripesh Sadasukhi, Priyatham Kasaraneni, Amitabh Singh, Kush Gupta, Girish Sharma, Vineet Talwar, Sudhir Kumar Rawal
2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience. Indian journal of cancer 60 (4) (2024)
Jiten Jaipuria, Ankita Jain, Shashikant Gupta, Nripesh Sadasukhi, Priyatham Kasaraneni, Amitabh Singh, Kush Gupta, Girish Sharma, Vineet Talwar, Sudhir Kumar Rawal
2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience. Indian journal of cancer (2024)